M. Alberti

Immunotherapy in NSCLC Patients with Brain Metastases

G. Fasola, A. Follador, F. Cortiula, 2022, International journal of molecular sciences.

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

F. Puglisi, G. Toffoli, R. Roncato, 2022, Frontiers in Pharmacology.

Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects

F. Puglisi, P. Di Nardo, C. Lisanti, 2022, Expert opinion on drug safety.

Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: current evidence and new perspectives.

G. Fasola, F. Puglisi, A. Michelotti, 2023, Critical reviews in oncology/hematology.

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.

D. de Ruysscher, R. Wijsman, L. Hendriks, 2023, European journal of cancer.

A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.

M. Montico, F. Puglisi, G. Toffoli, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

"A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".

F. Puglisi, G. Toffoli, S. Gagno, 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

G. Fasola, F. Puglisi, A. Minisini, 2021, Breast.